Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 2 Trials

Austin, Texas

Phase 2 colorectal cancer trials in Austin, TX

4 Phase 2 colorectal cancer studies are recruiting participants at sites in Austin as of November 18, 2026, according to ClinicalTrials.gov. Colorectal Phase 2 Trials can help you understand your options and connect with a study team.

Call (888) 467-9061
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Austin at a glance

  • 4 studies are recruiting at a site in Austin.
  • By phase: Phase 2 (4).
  • By sponsor: industry (3), university, hospital or other (1).
  • Most recent update to one of these records: October 27, 2026.

Studies recruiting in Austin

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Texas Oncology - Austin Midtown /ID# 271354
    Registry record
    NCT06820463 · updated
  2. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Texas Oncology - Central/South Texas /ID# 275154
    Registry record
    NCT07023289 · updated
  3. Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Stingray Therapeutics
    Study site
    Texas Oncology- Austin
    Registry record
    NCT06589440 · updated
  4. A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SCRI Development Innovations, LLC
    Study site
    Texas Oncology - Central/South Texas
    Registry record
    NCT07011576 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Austin, TX on ClinicalTrials.gov.

Ask about studies near Austin

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 2, as each study is coded in the registry.

Colorectal Phase 2 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 467-9061

or send a short form

How should we reach you?

Call